Titers of neutralizing antibodies were undetectable or low in fgl2+/+mice at all the time-points following infection, whereas fgl2−/− mice developed clinically significant titers of neutralizing antibodies towards LCMV WE as early as 12 weeks pi and peaking at week 16 pi (Figure 5C). This evidence concerns the gene FGL2 and infection.